Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10907480 | Experimental Hematology | 2008 | 11 Pages |
Abstract
In humans, mutations in ppox result in variegate porphyria. At present, effective treatment for acute attacks requires the administration intravenous hemin and/or glucose. Thus, mno represents a powerful model for investigation, and a tool for future screens aimed at identifying chemical modifiers of variegate porphyria.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Kimberly A. Dooley, Paula G. Fraenkel, Nathaniel B. Langer, Bettina Schmid, Alan J. Davidson, Gerhard Weber, Ken Chiang, Helen Foott, Caitlin Dwyer, Rebecca A. Wingert, Yi Zhou, Barry H. Paw, Leonard I. Zon,